Reyon Pharmaceutical Co Ltd (102460) — Capital Reinvestment Ratio
Reyon Pharmaceutical Co Ltd (102460) has a Capital Reinvestment Ratio of 1.76x as of March 2025, meaning it reinvests 2% of its operating cash flow (₩2.41 Billion) in capital expenditures (₩4.25 Billion). Check 102460 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Reyon Pharmaceutical Co Ltd Capital Reinvestment Ratio (2008–2023)
This chart tracks Reyon Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see 102460 cash generation efficiency.
Annual Capital Reinvestment Ratio for Reyon Pharmaceutical Co Ltd (2008–2023)
Year-by-year Capital Reinvestment Ratio for Reyon Pharmaceutical Co Ltd from 2008 to 2023. See free cash flow generation of Reyon Pharmaceutical Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 3.34x | ₩8.65 Billion | ₩28.87 Billion | ▼ -53.8% |
| 2022 | 7.23x | ₩8.73 Billion | ₩63.13 Billion | ▼ -27.8% |
| 2021 | 10.01x | ₩11.68 Billion | ₩116.98 Billion | ▼ -12.0% |
| 2020 | 11.37x | ₩4.60 Billion | ₩52.31 Billion | ▲ +232.4% |
| 2018 | 3.42x | ₩11.45 Billion | ₩39.17 Billion | ▲ +1284.1% |
| 2017 | 0.25x | ₩16.76 Billion | ₩4.14 Billion | ▼ -27.1% |
| 2016 | 0.34x | ₩9.47 Billion | ₩3.21 Billion | ▲ +245.5% |
| 2012 | 0.10x | ₩24.65 Billion | ₩2.42 Billion | ▼ -37.8% |
| 2011 | 0.16x | ₩15.34 Billion | ₩2.42 Billion | ▼ -6.2% |
| 2009 | 0.17x | ₩8.68 Billion | ₩1.46 Billion | ▼ -51.1% |
| 2008 | 0.34x | ₩5.99 Billion | ₩2.06 Billion | — |